Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells

Acta Neuropathologica

Volumn 125, Issue 6, 2013, Pages 891-900

  Koelsche, Christian ^a,b   Wöhrer, Adelheid ^c   Jeibmann, Astrid ^d   Schittenhelm, Jens ^e   Schindler, Genevieve ^f   Preusser, Matthias ^g   Lasitschka, Felix ^a   Von Deimling, Andreas ^a,b   Capper, David ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BRAF; BRAF V600E; Brain; Ganglioglioma; Tumor; VE1

Indexed keywords

B RAF KINASE; CD34 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMOSIDERIN; MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; DNA SEQUENCE; ENZYME PHOSPHORYLATION; FEMALE; GLIA CELL; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; TUMOR CELL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEASIBILITY STUDIES; FEMALE; GANGLIOGLIOMA; HUMANS; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878608078     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1100-2     Document Type: Article

References (46)

1. Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Brocker EB, Straten P, Rapp UR, Becker JC (2004) Immunogenicity of constitutively active V599EBRaf. Cancer Res 64(15):5456-5460. doi: 10.1158/0008-5472.CAN-04-0937
2. Becker AJ, Lobach M, Klein H, Normann S, Nothen MM, von Deimling A, Mizuguchi M, Elger CE, Schramm J, Wiestler OD, Blumcke I (2001) Mutational analysis of TSC1 and TSC2 genes in gangliogliomas. Neuropathol Appl Neurobiol 27(2):105-114
3. Bosmuller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F (2012) Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol doi: 10.1016/j.humpath.2012.07.010
4. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, Dalton J, Zambetti GP, Ellison DW, Kun LE, Gajjar A, Gilbertson RJ, Fuller CE (2007) Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 25(6):682-689. doi: 10.1200/JCO.2006.06.8213
5. Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Learoyd DL, Capper D, von Deimling A, Clifton-Bligh RJ, Gill AJ (2012) Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma. Endocr Relat Cancer 19(6):779-784. doi: 10.1530/ERC-12-0239
6. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M (2012) Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 123(2):223-233. doi: 10.1007/s00401-011-0887-y
7. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122(1):11-19. doi: 10.1007/s00401-011-0841-z
8. Caunt CJ, Keyse SM (2012) Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. doi: 10.1111/j.1742-4658.2012.08716.x
9. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, Blons H, Zimmermann U, Clerici T, Saiag P, Emile JF (2013) Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 15(1):94-100. doi: 10.1016/j.jmoldx.2012.09.001
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954. doi: 10.1038/nature00766
11. DeMarchi R, Abu-Abed S, Munoz D, Loch Macdonald R (2011) Malignant ganglioglioma: case report and review of literature. J Neurooncol 101(2):311-318. doi: 10.1007/s11060-010-0248-z
12. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S (2011) BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 6(3):e17948. doi: 10.1371/journal.pone. 0017948
13. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 12(7):621-630. doi: 10.1093/neuonc/noq007
14. Dougherty MK, Morrison DK (2004) Unlocking the code of 14-3-3. J Cell Sci 117(Pt 10):1875-1884. doi: 10.1242/jcs.01171
15. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, Lundeberg J (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16(6):471-478. doi: 10.1097/01.cmr.0000232300. 22032.86
16. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T (2011) Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129(9):2297-2303. doi: 10.1002/ijc.25893
17. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, Chaplin T, Carter RL, Gajjar A, Broniscer A, Young BD, Ellison DW, Sheer D (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218(2):172-181. doi: 10.1002/path.2558
18. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A (2003) Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162(6):1807-1815. doi: 10.1016/S0002-9440(10)64315-5
19. Gilles FH, Sobel EL, Tavare CJ, Leviton A, Hedley-Whyte ET (1995) Age-related changes in diagnoses, histological features, and survival in children with brain tumors: 1930-1979. The Childhood Brain Tumor Consortium. Neurosurgery 37(6):1056-1068
20. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118(4):469-474. doi: 10.1007/s00401-009-0561-9
21. Hasselblatt M, Riesmeier B, Lechtape B, Brentrup A, Stummer W, Albert FK, Sepehrnia A, Ebel H, Gerss J, Paulus W (2011) BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol 37(7):803-806. doi: 10.1111/j.1365-2990.2011.01193.x
22. Hoischen A, Ehrler M, Fassunke J, Simon M, Baudis M, Landwehr C, Radlwimmer B, Lichter P, Schramm J, Becker AJ, Weber RG (2008) Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH. Brain Pathol 18(3):326-337. doi: 10.1111/j.1750-3639. 2008.00122.x
23. Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis DN, Perry A, Murdoch G, Nikiforova M (2011) Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol 21(5):564-574. doi: 10.1111/j.1750-3639.2011.00480.x
24. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garami M, Bognar L, Hanzely Z, Montes JL, Atkinson J, Farmer JP, Bouffet E, Hawkins C, Tabori U, Jabado N (2009) Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 101(4):722-733. doi: 10.1038/sj.bjc.6605179
25. Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D, Garami M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Hawkins C, Korshunov A, Collins VP, Pfister SM, Tabori U, Jabado N (2011) Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 17(14):4650-4660. doi: 10.1158/1078-0432.CCR-11- 0127
26. Jaffey PB, Mundt AJ, Baunoch DA, Armstrong DL, Hamilton WJ, Zagaja VG, Grossman RG, Wollmann RL (1996) The clinical significance of extracellular matrix in gangliogliomas. J Neuropathol Exp Neurol 55(12):1246-1252
27. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68(21):8673-8677. doi: 10.1158/0008-5472.CAN-08-2097
28. Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 108(6):467-470. doi: 10.1007/s00401-004-0929-9
29. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M (2012) Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 36(6):844-850. doi: 10.1097/PAS.0b013e318246b527
30. Li WQ, Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Iacopetta B (2006) BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 5:2. doi: 10.1186/1476-4598-5-2
31. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, Putti TC, Guy GR (2004) The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 64(17):6127-6136. doi: 10.1158/0008-5472.CAN-04-1207
32. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29(10):1239-1246. doi: 10.1200/JCO.2010.32.4327
33. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA (2013) Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 37(1):61-65. doi: 10.1097/PAS.0b013e31826485c0
34. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109. doi: 10.1007/s00401-007-0243-4
35. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4(11):e7887. doi: 10.1371/journal.pone.0007887
36. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W, Omran H, Lichter P (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118(5):1739-1749. doi: 10.1172/JCI33656
37. Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, Cohen KJ, Eberhart CG (2011) BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res 17(11):3590-3599. doi: 10.1158/1078-0432.CCR- 10-3349
38. Remmele W, Hildebrand U, Hienz HA, Klein PJ, Vierbuchen M, Behnken LJ, Heicke B, Scheidt E (1986) Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer. Virchows Arch A Pathol Anat Histopathol 409(2):127-147
39. Rush S, Foreman N, Liu A (2013) Brainstem Ganglioglioma Successfully Treated With Vemurafenib. J Clin Oncol. doi: 10.1200/JCO.2012.44.1568
40. Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Mullauer L, Mechtersheimer G, von Deimling A (2012) BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 120(12):e28-e34. doi: 10.1182/blood-2012-06-429597
41. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2):512-519. doi: 10.1158/0008-5472.CAN-09-1851
42. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397-405. doi: 10.1007/s00401-011-0802-6
43. Scoccianti S, Giordano F, Agresti B, Detti B, Cipressi S, Franceschini D, Greto D, Mussa F, Sardi I, Buccoliero A, Arico M, Genitori L, Biti G (2012) Pediatric primary anaplastic ganglioglioma: a case report and review of the literature. Pediatr Neurosurg 48(1):35-41. doi: 10.1159/000340067
44. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P (2012) Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 67(3):488-491. doi: 10.1016/j.jaad.2012.03.022
45. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber BL (2004) SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 64(16):5556-5559. doi: 10.1158/0008-5472.CAN- 04-1669
46. Zhu JJ, Leon SP, Folkerth RD, Guo SZ, Wu JK, Black PM (1997) Evidence for clonal origin of neoplastic neuronal and glial cells in gangliogliomas. Am J Pathol 151(2):565-571